Argenx Gains European Approval for Novel CIDP Treatment

Argenx Se ( (ARGX) ) has provided an update.

On June 20, 2025, Argenx SE announced that the European Commission approved VYVGART® (efgartigimod alfa) for subcutaneous injection as a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. This approval, based on the ADHERE clinical trial, marks the first novel treatment mechanism for CIDP in over 30 years, offering a new targeted therapy option for patients. The approval is expected to enhance Argenx’s market position in Europe and provide significant benefits to patients suffering from this debilitating condition.

The most recent analyst rating on (ARGX) stock is a Buy with a $514.00 price target. To see the full list of analyst forecasts on Argenx Se stock, see the ARGX Stock Forecast page.

Spark’s Take on ARGX Stock

According to Spark, TipRanks’ AI Analyst, ARGX is a Neutral.

Argenx Se’s strong financial performance, highlighted by impressive revenue growth and a robust earnings call, boosts its overall score. However, mixed technical indicators and valuation challenges slightly temper the outlook.

To see Spark’s full report on ARGX stock, click here.

More about Argenx Se

Argenx is a global immunology company dedicated to improving the lives of individuals with severe autoimmune diseases. Through its Immunology Innovation Program, the company collaborates with leading academic researchers to develop a portfolio of novel antibody-based medicines. Argenx is known for commercializing the first approved neonatal Fc receptor (FcRn) blocker and is exploring its potential in various serious autoimmune diseases.

Average Trading Volume: 404,872

Technical Sentiment Signal: Buy

Current Market Cap: $33.24B

See more data about ARGX stock on TipRanks’ Stock Analysis page.